Arch Biopartners Inc. (ACHFF)
USD 1.24
(0.81%)
USD 1.24
(0.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.32 Million CAD | -139.44% |
| 2022 | -1.38 Million CAD | -18.78% |
| 2021 | -1.16 Million CAD | 74.73% |
| 2020 | -4.62 Million CAD | -96.33% |
| 2019 | -2.35 Million CAD | 26.28% |
| 2018 | -3.19 Million CAD | -67.94% |
| 2017 | -1.9 Million CAD | -89.2% |
| 2016 | -1 Million CAD | -19.97% |
| 2015 | -839 Thousand CAD | -110.54% |
| 2014 | -398.5 Thousand CAD | -109.8% |
| 2013 | -189.95 Thousand CAD | 42.32% |
| 2012 | -329.31 Thousand CAD | 26.21% |
| 2011 | -446.26 Thousand CAD | 93.81% |
| 2010 | -7.21 Million CAD | -54.91% |
| 2009 | -4.65 Million CAD | -608.06% |
| 2008 | -657.52 Thousand CAD | -81.9% |
| 2007 | -361.47 Thousand CAD | -1884.16% |
| 2006 | -18.21 Thousand CAD | 95.06% |
| 2005 | -368.97 Thousand CAD | 71.11% |
| 2004 | -1.27 Million CAD | -145.93% |
| 2003 | -519.3 Thousand CAD | -70.61% |
| 2002 | -304.38 Thousand CAD | 87.31% |
| 2001 | -2.39 Million CAD | -125.41% |
| 2000 | -1.06 Million CAD | -26.88% |
| 1999 | -838.66 Thousand CAD | -9.84% |
| 1998 | -763.53 Thousand CAD | 71.22% |
| 1997 | -2.65 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -783.25 Thousand CAD | -420.63% |
| 2024 Q2 | -1.14 Million CAD | -46.63% |
| 2024 Q3 | -884.56 Thousand CAD | 22.98% |
| 2023 Q2 | -962.42 Thousand CAD | 55.4% |
| 2023 Q3 | -450.78 Thousand CAD | 53.16% |
| 2023 Q4 | 244.28 Thousand CAD | 154.19% |
| 2023 FY | -3.32 Million CAD | -139.44% |
| 2023 Q1 | -2.15 Million CAD | -373.32% |
| 2022 Q4 | -455.89 Thousand CAD | -72.28% |
| 2022 Q3 | -264.62 Thousand CAD | 45.74% |
| 2022 Q2 | -487.7 Thousand CAD | -179.08% |
| 2022 Q1 | -174.75 Thousand CAD | -126.42% |
| 2022 FY | -1.38 Million CAD | -18.78% |
| 2021 Q1 | -1.65 Million CAD | -2.64% |
| 2021 Q4 | 661.36 Thousand CAD | -24.61% |
| 2021 FY | -1.16 Million CAD | 74.73% |
| 2021 Q3 | 877.24 Thousand CAD | 183.35% |
| 2021 Q2 | -1.05 Million CAD | 36.31% |
| 2020 Q1 | -733.04 Thousand CAD | 24.73% |
| 2020 Q2 | -95.34 Thousand CAD | 86.99% |
| 2020 Q3 | -2.19 Million CAD | -2197.24% |
| 2020 Q4 | -1.61 Million CAD | 26.49% |
| 2020 FY | -4.62 Million CAD | -96.33% |
| 2019 Q1 | -818.27 Thousand CAD | -4.08% |
| 2019 FY | -2.35 Million CAD | 26.28% |
| 2019 Q4 | -973.94 Thousand CAD | -1099.85% |
| 2019 Q2 | -513.74 Thousand CAD | 37.22% |
| 2019 Q3 | -81.17 Thousand CAD | 84.2% |
| 2018 Q2 | -584.09 Thousand CAD | -70.91% |
| 2018 Q3 | -1.48 Million CAD | -154.43% |
| 2018 Q1 | -341.76 Thousand CAD | -55.18% |
| 2018 FY | -3.19 Million CAD | -67.94% |
| 2018 Q4 | -786.22 Thousand CAD | 47.1% |
| 2017 Q1 | -235.35 Thousand CAD | 31.75% |
| 2017 Q2 | -154.32 Thousand CAD | 34.43% |
| 2017 Q4 | -220.23 Thousand CAD | 83.14% |
| 2017 FY | -1.9 Million CAD | -89.2% |
| 2017 Q3 | -1.3 Million CAD | -746.5% |
| 2016 FY | -1 Million CAD | -19.97% |
| 2016 Q2 | -322.86 Thousand CAD | -106.9% |
| 2016 Q3 | -182.81 Thousand CAD | 43.38% |
| 2016 Q4 | -344.84 Thousand CAD | -88.64% |
| 2016 Q1 | -156.04 Thousand CAD | -6.8% |
| 2015 FY | -839 Thousand CAD | -110.54% |
| 2015 Q1 | -358.86 Thousand CAD | -129.81% |
| 2015 Q4 | -146.1 Thousand CAD | 11.91% |
| 2015 Q3 | -165.86 Thousand CAD | 1.36% |
| 2015 Q2 | -168.16 Thousand CAD | 53.14% |
| 2014 Q1 | -52.87 Thousand CAD | 10.38% |
| 2014 FY | -398.5 Thousand CAD | -109.8% |
| 2014 Q2 | -58.61 Thousand CAD | -10.87% |
| 2014 Q4 | -156.15 Thousand CAD | -19.33% |
| 2014 Q3 | -130.86 Thousand CAD | -123.25% |
| 2013 Q1 | -32.62 Thousand CAD | 64.94% |
| 2013 FY | -189.95 Thousand CAD | 42.32% |
| 2013 Q4 | -58.99 Thousand CAD | -226.27% |
| 2013 Q2 | -80.24 Thousand CAD | -145.98% |
| 2013 Q3 | -18.08 Thousand CAD | 77.47% |
| 2012 Q4 | -93.04 Thousand CAD | -4.28% |
| 2012 Q3 | -89.22 Thousand CAD | -49.14% |
| 2012 FY | -329.31 Thousand CAD | 26.21% |
| 2012 Q1 | -87.22 Thousand CAD | 1.86% |
| 2012 Q2 | -59.82 Thousand CAD | 31.41% |
| 2011 Q1 | -107.58 Thousand CAD | -33.93% |
| 2011 Q3 | -173.46 Thousand CAD | -127.21% |
| 2011 FY | -446.26 Thousand CAD | 93.81% |
| 2011 Q4 | -88.87 Thousand CAD | 48.76% |
| 2011 Q2 | -76.34 Thousand CAD | 29.04% |
| 2010 Q4 | -80.33 Thousand CAD | 98.87% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2010 Q3 | -7.1 Million CAD | -29443.32% |
| 2010 FY | -7.21 Million CAD | -54.91% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2009 Q1 | -283.81 Thousand CAD | -2118.36% |
| 2009 Q2 | 549.65 Thousand CAD | 293.67% |
| 2009 Q3 | -5.07 Million CAD | -1024.21% |
| 2009 FY | -4.65 Million CAD | -608.06% |
| 2009 Q4 | -26.76 Thousand CAD | 99.47% |
| 2008 Q3 | -175.47 Thousand CAD | 5.37% |
| 2008 Q1 | -206.07 Thousand CAD | -270.38% |
| 2008 FY | -657.52 Thousand CAD | -81.9% |
| 2008 Q4 | -12.79 Thousand CAD | 92.71% |
| 2008 Q2 | -185.43 Thousand CAD | 10.01% |
| 2007 FY | -361.47 Thousand CAD | -1884.16% |
| 2007 Q3 | -33.89 Thousand CAD | 48.55% |
| 2007 Q4 | -55.63 Thousand CAD | -64.17% |
| 2007 Q2 | -65.87 Thousand CAD | -133.16% |
| 2007 Q1 | 198.63 Thousand CAD | 435.69% |
| 2006 Q1 | -185.68 Thousand CAD | -242.7% |
| 2006 Q2 | -108.1 Thousand CAD | 41.78% |
| 2006 Q3 | -49.57 Thousand CAD | 54.14% |
| 2006 Q4 | -59.17 Thousand CAD | -19.35% |
| 2006 FY | -18.21 Thousand CAD | 95.06% |
| 2005 FY | -368.97 Thousand CAD | 71.11% |
| 2005 Q4 | 130.11 Thousand CAD | 192.4% |
| 2005 Q3 | -140.82 Thousand CAD | 18.4% |
| 2005 Q2 | -172.58 Thousand CAD | 78.52% |
| 2005 Q1 | -803.56 Thousand CAD | -117.08% |
| 2004 Q1 | -330.51 Thousand CAD | -238.88% |
| 2004 Q4 | -370.16 Thousand CAD | -1757.85% |
| 2004 Q3 | 22.32 Thousand CAD | 118.15% |
| 2004 FY | -1.27 Million CAD | -145.93% |
| 2004 Q2 | -123.04 Thousand CAD | 62.77% |
| 2003 Q1 | -132.9 Thousand CAD | -671.49% |
| 2003 FY | -519.3 Thousand CAD | -70.61% |
| 2003 Q3 | -15.59 Thousand CAD | 79.39% |
| 2003 Q2 | -75.66 Thousand CAD | 43.07% |
| 2003 Q4 | -97.53 Thousand CAD | -525.4% |
| 2002 Q1 | -2.03 Million CAD | -2161.64% |
| 2002 FY | -304.38 Thousand CAD | 87.31% |
| 2002 Q3 | -82.08 Thousand CAD | -13.74% |
| 2002 Q4 | -17.22 Thousand CAD | 79.01% |
| 2002 Q2 | -72.16 Thousand CAD | 96.45% |
| 2001 FY | -2.39 Million CAD | -125.41% |
| 2001 Q3 | -235.8 Thousand CAD | -474.46% |
| 2001 Q2 | -41.04 Thousand CAD | 91.28% |
| 2001 Q1 | -470.77 Thousand CAD | -101.68% |
| 2001 Q4 | -89.85 Thousand CAD | 61.9% |
| 2000 FY | -1.06 Million CAD | -26.88% |
| 2000 Q3 | -300.81 Thousand CAD | -408.9% |
| 2000 Q4 | -233.42 Thousand CAD | 22.4% |
| 2000 Q2 | -59.11 Thousand CAD | 89.4% |
| 2000 Q1 | -557.43 Thousand CAD | -565.37% |
| 1999 Q2 | -69.15 Thousand CAD | 86.82% |
| 1999 Q1 | -524.85 Thousand CAD | -847.56% |
| 1999 FY | -838.66 Thousand CAD | -9.84% |
| 1999 Q3 | -128.29 Thousand CAD | -85.5% |
| 1999 Q4 | -83.77 Thousand CAD | 34.7% |
| 1998 Q2 | -127.9 Thousand CAD | 0.0% |
| 1998 Q4 | -55.39 Thousand CAD | 56.69% |
| 1998 FY | -763.53 Thousand CAD | 71.22% |
| 1998 Q3 | -127.9 Thousand CAD | 0.0% |
| 1997 FY | -2.65 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 106.279% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 52.358% |
| CSL Limited | 2.64 Billion USD | 100.126% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.108% |
| Regen BioPharma, Inc. | 1.02 Million USD | 425.032% |
| BioStem Technologies, Inc. | -8.48 Million USD | 60.784% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 12.89% |
| Qrons Inc. | -789.34 Thousand USD | -321.453% |
| Nascent Biotech, Inc. | -2.08 Million USD | -59.35% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.686% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 57.906% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.163% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -700.697% |
| Rebus Holdings, Inc. | -1.02 Million USD | -226.15% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 79.04% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -149.113% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.516% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -426.042% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.562% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 49.412% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1116.79% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.814% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -15.016% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -82.734% |
| Mesoblast Limited | -87.95 Million USD | 96.218% |
| Marizyme, Inc. | -65.34 Million USD | 94.909% |
| Genus plc | 7.9 Million USD | 142.11% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 69.456% |
| Pharming Group N.V. | -10.54 Million USD | 68.461% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -53.319% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 10.336% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 62.384% |
| ContraFect Corporation | -65.15 Million USD | 94.894% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 31.914% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -92.58% |
| IMV Inc. | -36.48 Million USD | 90.882% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 58.724% |
| MultiCell Technologies, Inc. | -380.07 USD | -875193.499% |
| ONE Bio Corp. | 8.67 Million USD | 138.341% |
| Accustem Sciences Inc. | -3.74 Million USD | 11.202% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.564% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -162.54% |
| Q BioMed Inc. | -2.05 Million USD | -62.114% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 10.883% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -39.727% |
| Biomind Labs Inc. | -1.21 Million USD | -173.958% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.43% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -7.253% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -70.667% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -22113.729% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 42.813% |
| GB Sciences, Inc. | -1.36 Million USD | -144.311% |
| Alpha Cognition Inc. | -13.77 Million USD | 75.845% |
| HST Global, Inc. | -146.21 Thousand USD | -2175.308% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -89.582% |
| Halberd Corporation | -79.67 Thousand USD | -4075.32% |
| Enzolytics Inc. | -2.17 Million USD | -52.824% |
| Agentix Corp. | -1.37 Million USD | -142.083% |
| Resverlogix Corp. | -3.61 Million USD | 7.847% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -4.897% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.872% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3494.62% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 148.042% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 16.266% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -9.933% |
| AVAX Technologies, Inc. | -6.41 Million USD | 48.13% |
| Zenith Capital Corp. | -10.59 Million USD | 68.604% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -14213.433% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 19.759% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5404.127% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -65.912% |
| Kadimastem Ltd | -3.3 Million USD | -0.584% |
| Helix BioMedix, Inc. | -1.05 Million USD | -215.014% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -653.729% |
| LadRx Corporation | 400.44 Thousand USD | 930.762% |
| Cell Source, Inc. | -5.32 Million USD | 37.482% |
| Regen BioPharma, Inc. | 1.02 Million USD | 425.032% |
| NovAccess Global Inc. | -4.76 Million USD | 30.245% |
| Affymax, Inc. | -14.42 Million USD | 76.936% |
| Itoco Inc. | -1.86 Million USD | -77.996% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 25.116% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -99.325% |
| Mobile Lads Corp. | -2.26 Million USD | -46.986% |
| CytoDyn Inc. | -49.84 Million USD | 93.325% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4109.29% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1358.279% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -253.333% |
| SYBLEU INC | -180.3 Thousand USD | -1745.066% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -106.278% |
| International Stem Cell Corporation | -131 Thousand USD | -2439.487% |
| Bioxytran, Inc. | -4.28 Million USD | 22.273% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6029.732% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -31.478% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.08% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -57.367% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -326.019% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -5.01% |
| Neutra Corp. | -233.46 Thousand USD | -1324.937% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 83.605% |
| PureTech Health plc | -65.69 Million USD | 94.936% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 84.357% |
| IXICO plc | -1.17 Million USD | -182.405% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 66.488% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.177% |
| CSL Limited | 2.64 Billion USD | 100.126% |
| Cellectis S.A. | -103.17 Million USD | 96.776% |